Has Sayed Mehdi Hamadani, MD received payments from drug or device companies?

Yes. Drug and device makers reported $545,806 in general payments to Sayed Mehdi Hamadani, MD across 341 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sayed Mehdi Hamadani, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sayed Mehdi Hamadani, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sayed Mehdi Hamadani, MD

Hematology & Oncology · Milwaukee, WINPI 1114142064

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $400,691 of the $545,806 with a category attached, or 73.4%. 25 manufacturers reported payments, led by ADC Therapeutics America, Inc. at 24.8% of the total. 2025 is the largest year on record at $148,354, 2.5 times the $58,852 reported in 2019. Among hematology & oncology clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$545,806in general payments, 2019–2025

Across 341 payments — averaging $1600.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

ADC Therapeutics America, Inc.$135K
Beigene USA, Inc.$96K
Gilead$82K
AstraZeneca$78K
Sanofi-aventis U.S. LLC$29K
Sanofi$22K
plus $104K from 19 others

$3,175,923in research payments, 2019–2025

Across 383 payments — averaging $8292.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Kyowa Kirin Services Ltd$1M
Bristol Myers Squibb$460K
Incyte Corporation$408K
Genentech, Inc.$390K
ADC Therapeutics America, Inc.$295K
National Marrow Donor Program$125K
plus $478K from 12 others

What the payments were for

Consulting fees$85,13316%
Speaking & faculty fees$400,69173%
Travel & lodging$51,5069%
Food & beverage$8,4752%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
ADC Therapeutics America, Inc.	87	$135,450
Beigene USA, Inc.	59	$96,472
Gilead(2 entities)	36	$82,351
AstraZeneca	44	$77,606
Sanofi-aventis U.S. LLC	10	$28,786
Sanofi	9	$21,531
Genentech, Inc.	5	$15,476
E.r. Squibb & Sons, L.L.C.	4	$14,222
Bristol Myers Squibb	15	$9,627
Incyte Corporation	12	$9,626
Beone Medicines USA, Inc.	4	$9,112
Omeros Corporation	14	$8,322
AbbVie	10	$7,012
Swedish Orphan Biovitrum AB	2	$6,938
Seagen Inc.	5	$5,383
Verastem, Inc.	2	$4,084
Genmab U.S., Inc.	4	$3,504
National Marrow Donor Program	9	$2,483
Daiichi Sankyo Inc.	2	$2,401
Novartis	2	$1,859
Janssen Scientific Affairs, LLC	1	$1,750
Lilly USA, LLC	1	$1,350
F. Hoffmann-la Roche AG	2	$346
Gamida Cell Inc.	1	$101
Grifols USA, LLC	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

BRUKINSA$104,746
CALQUENCE$77,133
MOZOBIL$46,529
Yescarta$11,677
Non-Covered Product$11,128
Rituxan$7,191
EPKINLY$7,125
narsoplimab$6,191
ADCETRIS$5,231
Copiktra$4,084
REZUROCK$3,645
ZYNLONTA$3,238
VANFLYTa$2,401
CARVYKTI$1,750
KYMRIAH$1,572
Venclexta$338
Pomalyst$116
OMISIRGE$101

How this compares

$545,806 in reported general payments places this provider in the 95th percentile of 248 hematology & oncology providers in Wisconsin.

See all hematology & oncology providers in Wisconsin →

Medicare billing

Part B allowed, 2024

$33,913

Medicare patients

116

Services billed

349

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Acyclovir	44	$780
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim	13	$131

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Milwaukee

Parameswaran HariMilwaukee$1.3M
Binod DhakalMilwaukee$535K
Deepak KilariMilwaukee$359K
Ehab AtallahMilwaukee$344K
Nirav ShahMilwaukee$207K
Razelle KurzrockMilwaukee$199K
Syed AbutalibMilwaukee$154K
Patrick FoyMilwaukee$132K
Guru Subramanian Guru MurthyMilwaukee$113K
Renju Vechurettu RajMilwaukee$96K

See the full list for Wisconsin →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →